Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

Cannabidiol (CBD) is a non-psychoactive cannabinoid, and available evidence suggests potential efficacy in the treatment of many disorders. DehydraTECH™2.0 CBD is a patented capsule formulation that improves the bioabsorption of CBD. We sought to compare the effects of CBD and DehydraTECH™2.0 CBD ba...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Ana Batinic, Davorka Sutlović, Sendi Kuret, Antonela Matana, Marko Kumric, Josko Bozic, Zeljko Dujic
Materialtyp: Artikel
Språk:English
Publicerad: MDPI AG 2023-04-01
Serie:Pharmaceuticals
Ämnen:
cannabidiol
blood pressure
CYP P450 genes
GC-MS analysis
SNP genotyping
Länkar:https://www.mdpi.com/1424-8247/16/5/645

Internet

https://www.mdpi.com/1424-8247/16/5/645

Liknande verk